{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T14:11:17Z","timestamp":1782569477116,"version":"3.54.5"},"reference-count":39,"publisher":"The Journal of Rheumatology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>Tofacitinib has been investigated for the treatment of rheumatoid arthritis (RA) in phase III studies in which concomitant glucocorticoids (GC) were allowed. We analyzed the effect of GC use on efficacy outcomes in patients with RA receiving tofacitinib and\/or methotrexate (MTX) or conventional synthetic disease-modifying antirheumatic drugs (csDMARD) in these studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Our posthoc analysis included data from 6 phase III studies (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01039688\">NCT01039688<\/jats:ext-link>;  <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00814307\">NCT00814307<\/jats:ext-link>;  <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00847613\">NCT00847613<\/jats:ext-link>;  <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00853385\">NCT00853385<\/jats:ext-link>;  <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00856544\">NCT00856544<\/jats:ext-link>;  <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00960440\">NCT00960440<\/jats:ext-link>). MTX-naive patients or patients with inadequate response to csDMARD or biological DMARD received tofacitinib 5 or 10 mg twice daily alone or with csDMARD, with or without concomitant GC. Patients receiving GC (\u2264 10 mg\/day prednisone or equivalent) before enrollment maintained a stable dose throughout. Endpoints included the American College of Rheumatology (ACR) 20\/50\/70 response rates, rates of Clinical Disease Activity Index (CDAI)-defined low disease activity (LDA; CDAI \u2264 10) and remission (CDAI \u2264 2.8), and changes from baseline in CDAI, 28-joint count Disease Activity Score (DAS28-4)\u2013erythrocyte sedimentation rate (ESR), Health Assessment Questionnaire\u2013Disability Index (HAQ-DI), pain visual analog scale (VAS), and modified total Sharp score.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Of 3200 tofacitinib-treated patients, 1258 (39.3%) received tofacitinib monotherapy and 1942 (60.7%) received tofacitinib plus csDMARD; 1767 (55.2%) received concomitant GC. ACR20\/50\/70 response rates, rates of CDAI LDA and remission, and improvements in CDAI, DAS28-4-ESR, HAQ-DI, and pain VAS with tofacitinib were generally similar with or without GC in monotherapy and combination therapy studies. GC use did not appear to affect radiographic progression in tofacitinib-treated MTX-naive patients. MTX plus GC appeared to inhibit radiographic progression to a numerically greater degree than MTX alone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Concomitant use of GC with tofacitinib did not appear to affect clinical or radiographic efficacy. MTX plus GC showed a trend to inhibit radiographic progression to a greater degree than MTX alone.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.170486","type":"journal-article","created":{"date-parts":[[2017,11,15]],"date-time":"2017-11-15T20:25:38Z","timestamp":1510777538000},"page":"177-187","source":"Crossref","is-referenced-by-count":20,"title":["Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies"],"prefix":"10.3899","volume":"45","author":[{"given":"Christina","family":"Charles-Schoeman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd R.","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano A.F.","family":"Zerbini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eustratios","family":"Bananis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Fleischmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2017,11,15]]},"reference":[{"key":"2018112909375143000_45.2.177.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204627"},{"key":"2018112909375143000_45.2.177.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60826-4"},{"key":"2018112909375143000_45.2.177.3","first-page":"S32","article-title":"The impact of rheumatoid arthritis and treatment on patients\u2019 lives","volume":"28","author":"Strand","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909375143000_45.2.177.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207524"},{"key":"2018112909375143000_45.2.177.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204573"},{"key":"2018112909375143000_45.2.177.6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2018112909375143000_45.2.177.7","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/1756-185X.12754","article-title":"APLAR rheumatoid arthritis treatment recommendations","volume":"18","author":"Lau","year":"2015","journal-title":"Int J Rheum Dis"},{"key":"2018112909375143000_45.2.177.8","first-page":"152","article-title":"2012 Brazilian Society of Rheumatology Consensus for the treatment of rheumatoid arthritis","volume":"52","author":"da Mota","year":"2012","journal-title":"Rev Bras Reumatol"},{"key":"2018112909375143000_45.2.177.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.33383"},{"key":"2018112909375143000_45.2.177.10","doi-asserted-by":"publisher","DOI":"10.1002\/art.33419"},{"key":"2018112909375143000_45.2.177.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.24567"},{"key":"2018112909375143000_45.2.177.12","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2014.995875"},{"key":"2018112909375143000_45.2.177.13","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20494"},{"key":"2018112909375143000_45.2.177.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61424-X"},{"key":"2018112909375143000_45.2.177.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109071"},{"key":"2018112909375143000_45.2.177.16","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-4-201308200-00006"},{"key":"2018112909375143000_45.2.177.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310476"},{"key":"2018112909375143000_45.2.177.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.37816"},{"key":"2018112909375143000_45.2.177.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112072"},{"key":"2018112909375143000_45.2.177.20","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130683"},{"key":"2018112909375143000_45.2.177.21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13075-016-0932-2","article-title":"Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study","volume":"18","author":"Yamanaka","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2018112909375143000_45.2.177.22","first-page":"1647","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 8 years","volume":"68","author":"Wollenhaupt","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2018112909375143000_45.2.177.23","first-page":"2143","article-title":"A safety analysis of tofacitinib 5 mg twice daily administered as monotherapy or in combination with background conventional synthetic DMARDs in a Phase 3 rheumatoid arthritis population","volume":"67","author":"Kivitz","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2018112909375143000_45.2.177.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-207178"},{"key":"2018112909375143000_45.2.177.25","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/art.40189","article-title":"Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2018112909375143000_45.2.177.26","doi-asserted-by":"publisher","DOI":"10.1002\/art.21298"},{"key":"2018112909375143000_45.2.177.27","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0611-8"},{"key":"2018112909375143000_45.2.177.28","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-5-201203060-00004"},{"key":"2018112909375143000_45.2.177.29","first-page":"S68","article-title":"A dose of only 5 mg prednisolone daily retards radiographic progression in early rheumatoid arthritis - the Low-Dose Prednisolone Trial","volume":"29","author":"Wassenberg","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909375143000_45.2.177.30","doi-asserted-by":"crossref","unstructured":"Kirwan JR Bijlsma JW Boers M Shea BJ . Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007;CD006356.","DOI":"10.1002\/14651858.CD006356"},{"key":"2018112909375143000_45.2.177.31","doi-asserted-by":"publisher","DOI":"10.1002\/art.27592"},{"key":"2018112909375143000_45.2.177.32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204588"},{"key":"2018112909375143000_45.2.177.33","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.087833"},{"key":"2018112909375143000_45.2.177.34","doi-asserted-by":"crossref","first-page":"523","DOI":"10.7326\/M15-0919","article-title":"Long-term outcomes of patients with recent-onset rheumatoid arthritis after 10 years of tight controlled treatment: a randomized trial","volume":"164","author":"Markusse","year":"2016","journal-title":"Ann Intern Med"},{"key":"2018112909375143000_45.2.177.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2013.07.011"},{"key":"2018112909375143000_45.2.177.36","doi-asserted-by":"publisher","DOI":"10.1002\/art.27227"},{"key":"2018112909375143000_45.2.177.37","first-page":"303","article-title":"Glucocorticoid-sparing in patients suffering from rheumatoid arthritis and treated with tocilizumab: the SPARE-1 study","volume":"34","author":"Saraux","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909375143000_45.2.177.38","doi-asserted-by":"crossref","first-page":"e000228","DOI":"10.1136\/rmdopen-2015-000228","article-title":"Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study","volume":"2","author":"Alten","year":"2016","journal-title":"RMD Open"},{"key":"2018112909375143000_45.2.177.39","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s10067-016-3468-6","article-title":"Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM)","volume":"36","author":"Mueller","year":"2017","journal-title":"Clin Rheumatol"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.170486","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T14:22:14Z","timestamp":1543501334000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.170486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,15]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,2,1]]},"published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.3899\/jrheum.170486"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.170486","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,15]]}}}